DEF 14A: Salarius Pharmaceuticals Seeks Stockholder Approval for Reverse Stock Split to Regain Nasdaq Compliance

Salarius Pharmaceuticals is asking stockholders to approve a reverse stock split to increase its stock price and maintain its Nasdaq listing.

Summary

• Salarius Pharmaceuticals is holding a Special Meeting of Stockholders on May 9, 2024, to vote on a proposal to authorize a reverse stock split of its common stock at a ratio between 1:4 and 1:8.
• The Board of Directors will determine the specific ratio and timing of the reverse stock split, if approved.
• The primary reason for the reverse stock split is to increase the company's stock price to meet Nasdaq's minimum price per share requirement for continued listing.
• Salarius received a notice from Nasdaq in September 2023 indicating non-compliance with the Bid Price Rule, and was granted an extension until September 3, 2024, to regain compliance.
• If the company fails to regain compliance, its stock could be delisted from the Nasdaq Capital Market, leading to adverse consequences.
• The reverse stock split will affect all stockholders uniformly, except for minor adjustments due to fractional shares, which will be paid in cash.
• The company's authorized share capital will remain unchanged at 100,000,000 shares of common stock.
• The Board reserves the right to abandon the reverse stock split if it determines it's no longer in the company's best interest.
• Stockholders are also being asked to approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are insufficient votes to approve the Reverse Stock Split Proposal.

Sentiment

Score: 5

Explanation: The document is neutral in tone, presenting the facts of the proposed reverse stock split and the reasons behind it. While the reverse stock split is intended to address a negative situation (potential delisting), the document focuses on the procedural aspects and potential benefits of the proposal.

Positives

• A successful reverse stock split could help Salarius maintain its listing on the Nasdaq Capital Market, avoiding the negative consequences of delisting.
• The Board's flexibility to choose a ratio between 1:4 and 1:8 allows them to optimize the outcome based on market conditions.
• The company has obtained an extension from Nasdaq to regain compliance, providing additional time to implement the reverse stock split.

Negatives

• The reverse stock split may not proportionally increase the stock price, and the market price could be affected by other factors.
• The reduced number of outstanding shares after the split could harm the liquidity of the common stock.
• The reverse stock split could be viewed negatively by the market.
• The company could use the shares that are available for future issuance in dilutive equity financing transactions, or to oppose a hostile takeover attempt or delay or prevent changes in control or changes in or removal of management, including transactions that are favored by a majority of the stockholders or in which the stockholders might otherwise receive a premium for their shares over then-current market prices or benefit in some other manner.
• Some stockholders may end up with odd lots of shares, which can be more difficult to sell.

Risks

• The reverse stock split may not be effective in increasing the stock price or maintaining Nasdaq compliance.
• Delisting from the Nasdaq Capital Market could have significant adverse consequences for the company.
• The Board could use the authorized but unissued shares to deter takeover attempts, which may not be in the best interest of all stockholders.
• The company's future performance and market conditions could negatively impact the stock price, regardless of the reverse stock split.

Future Outlook

The company intends to implement a reverse stock split if approved by stockholders and deemed necessary by the Board to maintain Nasdaq compliance. The Board will determine the specific ratio and timing based on market conditions and the company's performance.

Management Comments

• The Board believes that the proposed reverse stock split is a potentially effective means for us to maintain compliance with the Nasdaq listing rules and to avoid, or at least mitigate, the likely adverse consequences of our common stock being delisted from the Nasdaq Capital Market by producing the immediate effect of increasing the bid price of our common stock.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low stock prices. Many biotech and pharmaceutical companies, especially those in the development stage, may face this situation due to the high-risk nature of drug development and the need for significant capital investment.

Comparison to Industry Standards

• Many companies in the biotechnology sector have used reverse stock splits to maintain their listing on exchanges.
• For example, companies like Agenus Inc. and Diffusion Pharmaceuticals Inc. have recently implemented reverse stock splits to regain compliance with Nasdaq's minimum bid price requirement.
• The success of a reverse stock split in maintaining listing and improving stock price varies depending on the company's underlying fundamentals and market conditions.
• Some companies have successfully maintained their listing and seen their stock price improve, while others have continued to struggle despite the reverse stock split.

Stakeholder Impact

• Shareholders will be impacted by the reverse stock split, potentially seeing a change in the number of shares they own and the market price per share.
• Employees may be affected by the company's ability to maintain its Nasdaq listing, which could impact morale and stock options.
• The company's customers and suppliers may be indirectly affected by the company's financial stability and access to capital.

Next Steps

• Stockholders will vote on the reverse stock split proposal at the Special Meeting on May 9, 2024.
• The Board will determine the specific ratio and timing of the reverse stock split if approved.
• The company will file a Certificate of Amendment with the Secretary of State of Delaware if the reverse stock split is implemented.
• The company will notify stockholders of the effective time of the reverse stock split and provide instructions for exchanging stock certificates.

Key Dates

Keywords

reverse stock split, Nasdaq, compliance, stock price, delisting, common stock, proxy statement, stockholders, Salarius Pharmaceuticals